- Home
- PSTV vs APM Comparison
PSTV vs APM Comparison
Compare PSTV & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- APM
- Stock Information
- Founded
- PSTV 1996
- APM 2010
- Country
- PSTV United States
- APM United Kingdom
- Employees
- PSTV N/A
- APM N/A
- Industry
- PSTV Medical/Dental Instruments
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- PSTV Health Care
- APM Health Care
- Exchange
- PSTV Nasdaq
- APM Nasdaq
- Market Cap
- PSTV 17.0M
- APM 18.9M
- IPO Year
- PSTV N/A
- APM 2018
- Fundamental
- Price
- PSTV $0.41
- APM $1.94
- Analyst Decision
- PSTV Strong Buy
- APM
- Analyst Count
- PSTV 4
- APM 0
- Target Price
- PSTV $7.88
- APM N/A
- AVG Volume (30 Days)
- PSTV 6.5M
- APM 20.5M
- Earning Date
- PSTV 11-13-2025
- APM 04-30-2025
- Dividend Yield
- PSTV N/A
- APM N/A
- EPS Growth
- PSTV N/A
- APM N/A
- EPS
- PSTV N/A
- APM N/A
- Revenue
- PSTV $5,317,000.00
- APM N/A
- Revenue This Year
- PSTV $2.95
- APM N/A
- Revenue Next Year
- PSTV $7.89
- APM N/A
- P/E Ratio
- PSTV N/A
- APM N/A
- Revenue Growth
- PSTV N/A
- APM N/A
- 52 Week Low
- PSTV $0.16
- APM $0.46
- 52 Week High
- PSTV $2.31
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- PSTV 39.93
- APM 51.58
- Support Level
- PSTV $0.39
- APM $1.64
- Resistance Level
- PSTV $0.52
- APM $2.65
- Average True Range (ATR)
- PSTV 0.05
- APM 0.20
- MACD
- PSTV -0.01
- APM -0.04
- Stochastic Oscillator
- PSTV 10.00
- APM 27.72
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.